LU91703I2 - Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®) - Google Patents
Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®)Info
- Publication number
- LU91703I2 LU91703I2 LU91703C LU91703C LU91703I2 LU 91703 I2 LU91703 I2 LU 91703I2 LU 91703 C LU91703 C LU 91703C LU 91703 C LU91703 C LU 91703C LU 91703 I2 LU91703 I2 LU 91703I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- galactosidase
- mammalian cell
- acid residues
- biologically active
- sialic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/983,451 US5401650A (en) | 1990-10-24 | 1992-11-30 | Cloning and expression of biologically active α-galactosidase A |
EP94902448A EP0670896B2 (fr) | 1992-11-30 | 1993-11-30 | Clonage et expression d'alpha-galactosidase a biologiquement active |
EP00200454A EP1020528A3 (fr) | 1992-11-30 | 1993-11-30 | Méthode de production de protéines secrétées |
Publications (1)
Publication Number | Publication Date |
---|---|
LU91703I2 true LU91703I2 (fr) | 2010-08-24 |
Family
ID=25529958
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91704C LU91704I2 (fr) | 1992-11-30 | 2010-06-24 | Agalsidase alfa et ses dérivées pharmaceutiquementacceptables (REPLAGAL®) |
LU91703C LU91703I2 (fr) | 1992-11-30 | 2010-06-24 | Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91704C LU91704I2 (fr) | 1992-11-30 | 2010-06-24 | Agalsidase alfa et ses dérivées pharmaceutiquementacceptables (REPLAGAL®) |
Country Status (14)
Country | Link |
---|---|
US (2) | US5401650A (fr) |
EP (4) | EP1942189B1 (fr) |
JP (2) | JP4005629B2 (fr) |
AT (2) | ATE213020T1 (fr) |
AU (1) | AU691795B2 (fr) |
CA (1) | CA2150555C (fr) |
DE (3) | DE122010000028I1 (fr) |
DK (3) | DK1942189T3 (fr) |
ES (3) | ES2344431T3 (fr) |
IL (4) | IL200005A (fr) |
LU (2) | LU91704I2 (fr) |
PT (3) | PT1942189E (fr) |
SE (1) | SE2210947T5 (fr) |
WO (1) | WO1994012628A1 (fr) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6846968B1 (en) * | 1988-02-26 | 2005-01-25 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
US20040064855A1 (en) * | 1988-02-26 | 2004-04-01 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
US5179023A (en) * | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
WO1994023070A1 (fr) * | 1993-03-26 | 1994-10-13 | New York Blood Center, Inc. | α-N-ACETYLGALACTOSAMINIDASE RECOMBINEE ET ADNc CODANT CETTE ENZYME |
US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
AU4424497A (en) * | 1996-09-13 | 1998-04-02 | Transkaryotic Therapies, Inc. | Therapy for alpha-galactosidase a deficiency |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
AU2012227349B2 (en) * | 1996-09-13 | 2015-12-24 | Shire Human Genetic Therapies, Inc. | Therapy for alpha-galactosidase A deficiency |
IL155588A0 (en) * | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
US6455037B1 (en) * | 1996-11-01 | 2002-09-24 | Mount Sinai School Of Medicine Of The City University Of New York | Cells expressing an αgala nucleic acid and methods of xenotransplantation |
US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
IL135578A0 (en) * | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
EP1658857A1 (fr) * | 1997-10-29 | 2006-05-24 | Genzyme Corporation | Compositions et méthodes pour le traitement de maladies lysosomales |
IL143558A0 (en) * | 1998-12-23 | 2002-04-21 | Regeneron Pharma | Method of enhancing the biological activity of ligands |
AU2012241170B2 (en) * | 1999-03-11 | 2016-07-28 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-Galactosidase A deficiency |
AU2016250357B2 (en) * | 1999-03-11 | 2018-11-01 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-Galactosidase A deficiency |
US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
US6770468B1 (en) | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
CN1312383A (zh) * | 2000-03-07 | 2001-09-12 | 上海博德基因开发有限公司 | 一种新的多肽——人alpha-半乳糖苷酶A-11和编码这种多肽的多核苷酸 |
US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US7629309B2 (en) * | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
CA2445577C (fr) * | 2001-04-30 | 2012-07-03 | Symbiontics, Inc. | Ciblage intracellulaire de proteines therapeutiques |
US20040005309A1 (en) * | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
JP4742191B2 (ja) * | 2001-06-14 | 2011-08-10 | 独立行政法人産業技術総合研究所 | 糖蛋白質およびその製造方法 |
US7767415B2 (en) | 2001-09-25 | 2010-08-03 | Velico Medical, Inc. | Compositions and methods for modifying blood cell carbohydrates |
CN105131104B (zh) | 2001-10-10 | 2018-11-16 | 诺和诺德公司 | 肽的重构和糖缀合 |
DK1578771T3 (da) | 2001-10-10 | 2013-06-10 | Novo Nordisk As | Remodellering og glycokonjugering af peptider |
US20030072761A1 (en) * | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
US6905856B2 (en) | 2001-12-21 | 2005-06-14 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
US20030124652A1 (en) * | 2001-12-21 | 2003-07-03 | Novazyme Pharmaceuticals, Inc. | Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells |
US6800472B2 (en) * | 2001-12-21 | 2004-10-05 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase |
WO2003086452A2 (fr) * | 2002-04-05 | 2003-10-23 | Genzyme Corporation | Procedes permettant d'ameliorer le traitement de maladies lysosomales |
NZ536361A (en) * | 2002-04-25 | 2008-05-30 | Shire Human Genetic Therapies | Treatment of alpha-galactosidase a deficiency |
ES2619353T3 (es) | 2003-01-31 | 2017-06-26 | Mount Sinai School Of Medicine Of New York University | Terapia de combinación para tratar trastornos de deficiencia de proteínas |
EP2338333B1 (fr) | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes |
US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
BRPI0416217A8 (pt) * | 2003-11-12 | 2018-05-08 | Amicus Therapeutics Inc | composto derivado de hidroxipiperidina, métodos para a síntese de um composto derivado de hidroxipiperidina para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase numa célula de mamífero e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir beta-glicosidade, e para tratar doença de gaucher e derivado hidroxipiperidina com ligante flexível curto |
WO2005078077A2 (fr) * | 2004-02-10 | 2005-08-25 | Zystor Therapeutics, Inc. | Alpha-glucosidase acide et fragments de celle-ci |
US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
CN101389273B (zh) * | 2004-08-05 | 2012-09-05 | 贝勒研究院 | 基因或药物递送系统 |
ES2572148T3 (es) | 2005-05-17 | 2016-05-30 | Amicus Therapeutics Inc | Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados |
US8470318B2 (en) | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
WO2007058381A1 (fr) * | 2005-11-18 | 2007-05-24 | Tokyo Metropolitan Organization For Medical Research | Nouvelle enzyme extrêmement fonctionnelle ayant une spécificité de substrat modifiée |
ES2391657T3 (es) | 2006-02-07 | 2012-11-28 | Shire Human Genetic Therapies, Inc. | Composiciones estabilizadas de proteínas que tienen un resto tiol libre |
GB0606190D0 (en) | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
EP2815768A3 (fr) * | 2006-04-05 | 2015-01-14 | The Rockefeller University | Polypeptides présentant des propriétés anti-inflammatoires accrues et des propriétés cytotoxiques réduites et procédés afférents |
JP2010509344A (ja) * | 2006-11-13 | 2010-03-25 | ザイストール セラピューティクス, インコーポレイテッド | ポンペ病を治療するための方法 |
EP2150608B1 (fr) | 2007-05-07 | 2017-11-29 | Protalix Ltd. | Bioréacteur jetable à grande échelle |
AU2008290217B2 (en) * | 2007-08-20 | 2013-09-05 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
DK2252313T3 (en) * | 2008-02-12 | 2015-07-13 | Amicus Therapeutics Inc | METHOD TO PREDICT response to Pharmacological chaperone TREATMENT OF DISEASES |
EP2279410B1 (fr) | 2008-04-22 | 2015-11-11 | The Rockefeller University | Procédés d'identification de composés anti-inflammatoires |
DK2279210T3 (en) | 2008-05-07 | 2017-07-24 | Biomarin Pharm Inc | Lysosomal targeting peptides and uses thereof |
US8592555B2 (en) * | 2008-08-11 | 2013-11-26 | Emd Millipore Corporation | Immunoglobulin-binding proteins with improved specificity |
CN102227638B (zh) * | 2008-09-30 | 2015-05-20 | Abbvie公司 | Rna展示的改良方法 |
SG195555A1 (en) * | 2008-12-24 | 2013-12-30 | Emd Millipore Corp | Caustic stable chromatography ligands |
US9050276B2 (en) | 2009-06-16 | 2015-06-09 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
ES2569514T3 (es) | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulaciones para enzimas lisosómicas |
RU2733466C2 (ru) | 2009-07-28 | 2020-10-01 | Шайр Хьюман Дженетик Терапиз | Композиции и способы для лечения болезни гоше |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
WO2011108451A1 (fr) * | 2010-03-01 | 2011-09-09 | 日本ケミカルリサーチ株式会社 | Procédé de production d'enzymes lysosomales recombinantes au moyen de cellules présentant une inactivation de gène |
WO2011107992A2 (fr) | 2010-03-02 | 2011-09-09 | Protalix Ltd. | Formes multimères de protéines thérapeutiques et leurs applications |
EP3088514B1 (fr) * | 2010-03-02 | 2018-11-28 | Protalix Ltd. | Alpha-galactosidase stabilisé et ses utilisations |
US9453847B2 (en) | 2010-07-19 | 2016-09-27 | Shire Human Genetic Therapies, Inc. | Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof |
US8679478B2 (en) | 2010-10-04 | 2014-03-25 | Duke University | Methods of lysosomal storage disease therapy |
CN103391784A (zh) | 2010-10-15 | 2013-11-13 | 纽约市哥伦比亚大学理事会 | 肥胖症-相关的基因和它们的蛋白和其用途 |
WO2012061537A2 (fr) | 2010-11-02 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Méthodes de traitement de troubles capillaires |
LT3272861T (lt) | 2011-01-20 | 2020-03-25 | Protalix Ltd. | Alfa-galaktozidazės kompozicijos |
SG10201604559TA (en) | 2011-06-08 | 2016-07-28 | Emd Millipore Corp | Chromatography matrices including novel staphylococcus aureus protein a based ligands |
DK2753346T3 (da) | 2011-09-07 | 2020-05-25 | Sinai School Medicine | Ceramidase og celledifferentiering |
KR20140138850A (ko) | 2012-03-02 | 2014-12-04 | 샤이어 휴먼 지네틱 테라피즈 인크. | Iii형 고셔병을 치료하기 위한 조성물 및 방법 |
KR20230066482A (ko) | 2012-03-07 | 2023-05-15 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
WO2013139861A1 (fr) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Procédés et compositions pharmaceutiques pour le traitement de troubles du syndrome de l'autisme |
HUE040127T2 (hu) | 2012-03-29 | 2019-02-28 | Univ Columbia | Eljárások hajhullási rendellenességek kezelésére |
HUE051020T2 (hu) | 2012-06-01 | 2021-01-28 | Icahn School Med Mount Sinai | A ceramid szintjei a fertõzések kezelésében és megelõzésében |
JP6226435B2 (ja) * | 2012-07-26 | 2017-11-08 | Jcrファーマ株式会社 | 組換えヒトα−ガラクトシダーゼAの製造方法 |
WO2014016873A1 (fr) | 2012-07-26 | 2014-01-30 | Jcr Pharmaceuticals Co., Ltd. | Procédé de production d'alpha-galactosidase a humaine recombinante |
ES2739811T3 (es) | 2013-03-14 | 2020-02-04 | Icahn School Med Mount Sinai | Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas |
MX2015012873A (es) * | 2013-03-15 | 2016-02-03 | Amicus Therapeutics Inc | Reticuladores quimicos. |
EA031652B1 (ru) * | 2013-09-16 | 2019-02-28 | Джензим Корпорейшн | Способ и система для обработки клеточной культуры |
TW202332774A (zh) * | 2013-10-23 | 2023-08-16 | 美商健臻公司 | 重組醣蛋白及其用途 |
US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
FI3201320T3 (fi) | 2014-09-30 | 2024-01-08 | Amicus Therapeutics Inc | Erittäin tehokas hapan alfa-glukosidaasi parannetuilla hiilihydraateilla |
WO2016116966A1 (fr) * | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Procédé de purification d'une alpha-galactosidase a recombinante humaine à partir de matériel contenant des protéines contaminantes des cellules hôtes |
US9981021B1 (en) | 2015-04-09 | 2018-05-29 | Kinetiq, Inc. | Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof |
EP3347486A4 (fr) | 2015-09-09 | 2019-06-19 | The Trustees of Columbia University in the City of New York | Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer |
US10940125B2 (en) | 2015-09-18 | 2021-03-09 | Duke University | Methods and compositions for the treatment of steatosis-associated disorders |
KR102510941B1 (ko) | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
CA3019128A1 (fr) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Formulations comprenant une alpha-glucosidase acide recombinante |
KR20220145918A (ko) | 2016-03-30 | 2022-10-31 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 고 m6p 재조합 단백질의 선택 방법 |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
WO2018071814A1 (fr) | 2016-10-14 | 2018-04-19 | The Trustees Of Columbia University In The City Of New York | Procédés de traitement d'un trouble d'abus d'alcool |
RU2698460C1 (ru) * | 2019-03-28 | 2019-08-27 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Способ получения рекомбинантной в-1,4-галактозидазы bgaa из streptococcus pneumoniae |
EP3996696A1 (fr) | 2019-07-09 | 2022-05-18 | Genethon | Traitement de la glycogénose (gsd) |
CN112795583A (zh) * | 2020-11-16 | 2021-05-14 | 上海大学 | 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法 |
CA3217356A1 (fr) * | 2021-04-20 | 2022-10-27 | Walking Fish Therapeutics, Inc. | Usines de proteines a base de lymphocytes b techniques pour traiter des maladies graves |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH585793A5 (fr) * | 1974-02-01 | 1977-03-15 | Nestle Sa | |
JPS5322158B2 (fr) * | 1974-05-02 | 1978-07-06 | ||
IT1130242B (it) * | 1980-02-01 | 1986-06-11 | Anic Spa | Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso |
US4925796A (en) * | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US5047335A (en) * | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
WO1990011353A1 (fr) * | 1989-03-24 | 1990-10-04 | Research Corporation Technologies, Inc. | Alpha-galactosidase de recombinaison, une therapie contre la maladie de fabry |
US5032519A (en) * | 1989-10-24 | 1991-07-16 | The Regents Of The Univ. Of California | Method for producing secretable glycosyltransferases and other Golgi processing enzymes |
DE4028800A1 (de) * | 1990-09-11 | 1992-03-12 | Behringwerke Ag | Gentechnische sialylierung von glykoproteinen |
US5382524A (en) * | 1990-10-24 | 1995-01-17 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-n-acetylgalactosaminidase |
-
1992
- 1992-11-30 US US07/983,451 patent/US5401650A/en not_active Expired - Lifetime
-
1993
- 1993-11-30 SE SE10157183T patent/SE2210947T5/xx unknown
- 1993-11-30 JP JP51342394A patent/JP4005629B2/ja not_active Expired - Lifetime
- 1993-11-30 DE DE122010000028C patent/DE122010000028I1/de active Pending
- 1993-11-30 CA CA2150555A patent/CA2150555C/fr not_active Expired - Lifetime
- 1993-11-30 AT AT94902448T patent/ATE213020T1/de not_active IP Right Cessation
- 1993-11-30 AU AU56817/94A patent/AU691795B2/en not_active Expired
- 1993-11-30 IL IL200005A patent/IL200005A/en not_active IP Right Cessation
- 1993-11-30 DK DK07022356.5T patent/DK1942189T3/da active
- 1993-11-30 DE DE69331550T patent/DE69331550T3/de not_active Expired - Lifetime
- 1993-11-30 PT PT07022356T patent/PT1942189E/pt unknown
- 1993-11-30 IL IL220131A patent/IL220131A0/en unknown
- 1993-11-30 IL IL220132A patent/IL220132A0/en unknown
- 1993-11-30 ES ES07022356T patent/ES2344431T3/es not_active Expired - Lifetime
- 1993-11-30 EP EP07022356A patent/EP1942189B1/fr not_active Expired - Lifetime
- 1993-11-30 ES ES94902448T patent/ES2168101T5/es not_active Expired - Lifetime
- 1993-11-30 DK DK94902448T patent/DK0670896T3/da active
- 1993-11-30 AT AT07022356T patent/ATE464386T1/de active
- 1993-11-30 EP EP00200454A patent/EP1020528A3/fr not_active Ceased
- 1993-11-30 PT PT94902448T patent/PT670896E/pt unknown
- 1993-11-30 WO PCT/US1993/011539 patent/WO1994012628A1/fr active IP Right Grant
- 1993-11-30 EP EP94902448A patent/EP0670896B2/fr not_active Expired - Lifetime
- 1993-11-30 PT PT101571834T patent/PT2210947E/pt unknown
- 1993-11-30 DE DE69334327T patent/DE69334327D1/de not_active Expired - Lifetime
- 1993-11-30 ES ES10157183T patent/ES2431293T3/es not_active Expired - Lifetime
- 1993-11-30 EP EP10157183.4A patent/EP2210947B1/fr not_active Expired - Lifetime
- 1993-11-30 DK DK10157183.4T patent/DK2210947T3/da active
- 1993-11-30 IL IL107814A patent/IL107814A/en active Protection Beyond IP Right Term
-
1994
- 1994-06-17 US US08/261,577 patent/US5580757A/en not_active Expired - Lifetime
-
2003
- 2003-12-01 JP JP2003401467A patent/JP3598302B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-24 LU LU91704C patent/LU91704I2/fr unknown
- 2010-06-24 LU LU91703C patent/LU91703I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU91703I2 (fr) | Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®) | |
BR9407907A (pt) | Processo para produzir uma substância alvo usando um microorganismo | |
ATE331731T1 (de) | Verfahren zur herstellung von diphtheria toxin | |
FR2726003B1 (fr) | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires | |
ES8202362A1 (es) | Procedimiento para preparar un acido desoxi-ribonucleico (adn) recombinante | |
ES8606489A1 (es) | Un metodo de producir una proteina de interleuquina-2-humana no glicosilada sustancialmente pura | |
EP0111389A3 (fr) | Hormone de croissance porcine substantiellement pure, séquences d'ADN pour celle-ci et vecteurs d'expression et microorganismes transfectés pour la production de l'hormone de croissance porcine | |
ES2188708T3 (es) | Metodo de produccion de acido l-lactico con alta pureza optica utilizando cepas de bacillus. | |
BR0309401A (pt) | polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo | |
EP0837931A4 (fr) | Procede d'expression et d'isolation de molecules biologiquement actives dans l'urine | |
DE59611099D1 (de) | Verfahren zur Nutzung des Hefe-ADH-II-Promotorsystems zur biotechnologischen Produktion heterologer Proteine in hohen Ausbeuten | |
KR930006117B1 (ko) | 동물세포 배양용 고농도 배지 및 배양공정 | |
ATE145670T1 (de) | Verfahren zur fermentativen herstellung von 2- hydroxyphenylessigsäure | |
DE3868712D1 (de) | Ein neues antibiotikum, fumifungin, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel. | |
TH7253B (th) | กระบวนการสำหรับผลิตอาเวอร์เมคตินbและเชื้อสำหรับผลิตสารเหล่านี้ | |
ZA878543B (en) | Method for the preparation of optically active bicyclo(3.3.0.)-octanedionecarboxylic acid esters | |
CA2058785A1 (fr) | Methode pour l'obtention de proteines avec des derives fviii et ou a activite fviii | |
JPS5668395A (en) | Production of d(-)-beta-hydroxyisobutyric acid | |
DE69429757T2 (de) | Verfahren zur Herstellung einer Substanz | |
TH9081A (th) | กระบวนการสำหรับผลิตอาเวอร์เมคตินbและเชื้อสำหรับผลิตสารเหล่านี้ | |
UA10461A (uk) | Іhдуктор іhтерфероhу в клітиhах ссавців, які культивуються |